Alectinib rescue therapy in advanced ALK rearranged lung adenocarcinoma: a case report
Abstract
Alectinib is a highly selective tyrosine kinase inhibitor of anaplastic lymphoma kinase (ALK) that is approved as first-line treatment in adult patients with ALK-positive non-small cell lung cancer (NSCLC) and as second-line in patients previously treated with crizotinib, and has been shown in the literature to significantly prolong progression-free survival compared to chemotherapy in patients with advanced non-small cell lung cancer. The authors describe a clinical case of a 24-year-old woman with malignant massive pleural effusion caused by ALK rearranged pulmonary adenocarcinoma with pleural and pericardial metastasis, in which, despite a dramatic clinical debut, the correct and timely management of the diagnostic and therapeutic path allowed for extraordinary therapeutic success.
References
- Porcel JM, Gasol A, Bielsa S, et al. Clinical features and survival of lung cancer patients with pleural effusions. Respirology 2015;20:654-9. DOI: https://doi.org/10.1111/resp.12496
- Comella P, Frasci G, De Cataldis G, et al. Cisplatin/carboplatin + etoposide + vinorelbine in advanced non-small-cell lung cancer: a multicentre randomised trial. Gruppo Oncologico Campano. Br J Cancer 1996;74:1805-11. DOI: https://doi.org/10.1038/bjc.1996.634
- Cattaneo F, Guerra G, Parisi M, et al. Expression of formyl-peptide receptors in human lung carcinoma. Anticancer Res 2015;35:2769-74.
- Bianco A, Perrotta F, Barra G, et al. Prognostic factors and biomarkers of responses to immune checkpoint inhibitors in lung cancer. Int J Mol Sci 2019;20:4931. DOI: https://doi.org/10.3390/ijms20194931
- Perrotta F, Rocco D, Vitiello F, et al. Immune checkpoint blockade for advanced NSCLC: A new landscape for elderly patients. Int J Mol Sci 2019;20:2258. DOI: https://doi.org/10.3390/ijms20092258
- Cameron LB, Hitchen N, Chandran E, et al. Targeted therapy for advanced anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer. Cochrane Database Syst Rev 2022;1:CD013453. DOI: https://doi.org/10.1002/14651858.CD013453.pub2
- Golding B, Luu A, Jones R, Viloria-Petit AM. The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC). Mol Cancer 2018;17:52. DOI: https://doi.org/10.1186/s12943-018-0810-4
- Moore DA, Benafif S, Poskitt B, et al. Optimising fusion detection through sequential DNA and RNA molecular profiling of non-small cell lung cancer. Lung Cancer 2021;161:55-9. DOI: https://doi.org/10.1016/j.lungcan.2021.08.008
- Doxtader EE, Cheng YW, Zhang Y. Molecular testing of non-small cell lung carcinoma diagnosed by endobronchial ultrasound-guided transbronchial fine-needle aspiration: The Cleveland clinic experience. Arch Pathol Lab Med 2019;143:670-6. DOI: https://doi.org/10.5858/arpa.2017-0184-RA
- Perrotta F, Nankivell M, Adizie JB, et al. Endobronchial ultrasound-guided transbronchial needle aspiration for PD-L1 testing in non-small cell lung cancer. Chest 2020;158:1230-9. DOI: https://doi.org/10.1016/j.chest.2020.04.059
- Ando K, Akimoto K, Sato H, et al. Brigatinib and alectinib for ALK rearrangement-positive advanced non-small cell lung cancer with or without central nervous system metastasis: A systematic review and network meta-analysis. Cancers (Basel) 2020;12:942. DOI: https://doi.org/10.3390/cancers12040942
- Serritella AV, Bestvina CM. Anaplastic lymphoma kinase mutation-positive non-small cell lung cancer. Thorac Surg Clin 2020;30:137-46. DOI: https://doi.org/10.1016/j.thorsurg.2019.12.001
Metrics
Citations and online attention from Dimensions, Altmetric and PlumX.
License
Copyright (c) 2022 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.